TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28199070

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 302

Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 302
Study: 25881268

Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks combined with 30-minute relaxing music
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no earplugs, eye masks, or music)
Number of subjects: 50
Study: 23890600

Group type: EXPERIMENTAL
Intervention: In-hospital polysomnography (PSG)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Postdischarge polysomnography (PSG)
Number of subjects: 160
Study: 21383291

Group type: EXPERIMENTAL
Intervention: 3-day oral aprepitant regimen (125 mg on day 1, 80 mg on day 2, 80 mg on day 3)
Number of subjects: 2247

Group type: COMPARATOR
Intervention: Single-dose intravenous fosaprepitant (150 mg on day 1)
Number of subjects: 2247
Study: 18504592

Group type: EXPERIMENTAL
Intervention: MR enteroclysis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Endoscopy (Rutgeerts score)
Number of subjects: 30
Study: 16052688

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with esophageal varices (EVB +)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients without esophageal variceal bleeding (EVB -)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with F1 varices
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with F2 and F3 varices
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with hepatofugal flow velocity >15 cm/s
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients after glucose ingestion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with hepatofugal blood flow in the LGV
Number of subjects: 120
Study: 10583029

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (0.44 mg day-1, 0.88 mg day-1, 1.76 mg day-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (5 mg day-1, 10 mg day-1, 20 mg day-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9060066

Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum KLD (10^10) b.i.d. for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 17
Study: 1652264

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg pipecuronium
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg pipecuronium
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study: 6848299

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol 400 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31998163

Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recreational Therapy (RT)
Number of subjects: 0
Study: 29278709

Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring (mean of 16.3 scans/day)
Number of subjects: 50831
Study: 27649854

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 25274860

Group type: EXPERIMENTAL
Intervention: Taxus stents
Number of subjects: 242

Group type: COMPARATOR
Intervention: BMS
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Taxus and BMS combined
Number of subjects: 242
Study: 23161305

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Number of subjects: 95

Group type: COMPARATOR
Intervention: Magnetic resonance cholangiopancreatography
Number of subjects: 95
Study: 18704471

Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg BD)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fexofenadine and nasal corticosteroids
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Airborne pollen exposure for 4 days prior to the study
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cumulative amount of airborne pollen during the treatment period
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Allergic history
Number of subjects: 105
Study: 18780501

Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Activator appliance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Herbst appliance
Number of subjects: 60
Study: 16045138

Group type: EXPERIMENTAL
Intervention: Ondansetron prophylaxis
Number of subjects: 34

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 34
Study: 11982836

Group type: EXPERIMENTAL
Intervention: Oxycodone premedication with halothane
Number of subjects: 130

Group type: COMPARATOR
Intervention: Halothane without oxycodone
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sevoflurane without oxycodone
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Oxycodone premedication with sevoflurane
Number of subjects: 130
Study: 10593449

Group type: EXPERIMENTAL
Intervention: Olanzapine 12.5 mg/day for the first week, then 25 mg/day for the remaining weeks (8 weeks total)
Number of subjects: 27
Study: 8618109

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg bid for 5 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg bid for 10 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin 25,000 U/kg tid for 10 days
Number of subjects: 120
Study: 2169839

Group type: EXPERIMENTAL
Intervention: Lactulose (15 ml bd)
Number of subjects: 43

Group type: COMPARATOR
Intervention: High-fibre diet (30-40 g daily)
Number of subjects: 43
Study: 7398187

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 2 gm in water
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Magnesium-aluminum hydroxide gel 30 ml
Number of subjects: 5

Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 5
Study: 31672946

Group type: EXPERIMENTAL
Intervention: Customized Health Promotion Program (CHPP) for 10 weeks, weekly sessions, including coping strategies, lifestyle modification, emotional support, and exercise three times a week at home
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study: 29712566

Group type: EXPERIMENTAL
Intervention: VRP (2.0) distal radius plate (Austofix)
Number of subjects: 200

Group type: COMPARATOR
Intervention: VA-LCP (Variable angle-locking plate) (Depuy-Synthes)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study: 26096162

Group type: EXPERIMENTAL
Intervention: Conical interface (CI)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Flat-to-flat interface (FI)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Platform switch interface (PS)
Number of subjects: 141

Group type: COMPARATOR
Intervention: All groups (CI, FI, PS)
Number of subjects: 141
Study: 24055737

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 22467891

Group type: EXPERIMENTAL
Intervention: Lidocaine block
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo block
Number of subjects: 12
Study: 19859781

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (S)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 17852171

Group type: EXPERIMENTAL
Intervention: Immediate treatment (n = 177)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Waiting list condition (n = 62)
Number of subjects: 239
Study: 15745977

Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase (250,000 IU twice daily for three days)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase
Number of subjects: 454
Study: 12414852

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T(4))
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 10492650

Group type: COMPARATOR
Intervention: Air
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CO
Number of subjects: 15
Study: 8961992

Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch-gelatin group
Number of subjects: 69

Group type: COMPARATOR
Intervention: Gelatin-only group
Number of subjects: 69
Study: 1742507

Group type: EXPERIMENTAL
Intervention: Oral bismuth therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ranitidine therapy
Number of subjects: 44
Study: 6125728

Group type: EXPERIMENTAL
Intervention: 200 mg acyclovir by mouth five times a day for 5 days
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 31931762

Group type: EXPERIMENTAL
Intervention: Decentralised NCD care delivered by nurse practitioners in community clinics
Number of subjects: 1125
Study: 29659406

Group type: EXPERIMENTAL
Intervention: Topical BTX‐A liposomal cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 20
Study: 26704774

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg) plus lidocaine (1.5 mg/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg) plus normal saline 0.9% (placebo)
Number of subjects: 110
Study: 25338456

Group type: EXPERIMENTAL
Intervention: Concentrations of nitric oxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity of oxistat
Number of subjects: 0
Study: 23724549

Group type: EXPERIMENTAL
Intervention: 1-step adhesives (XE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1-step adhesives (GB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1-step adhesives (CS3)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1-step adhesives (AD)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1-step adhesives (GO)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1-step adhesives (1-step ABSE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2-step adhesives (2-step ABSE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2-step adhesives (CSE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CSE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (2-step ABSE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (1-step ABSE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (AD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CS3)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (GB)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (GO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (XE)
Number of subjects: 8
Study: 19757215

Group type: EXPERIMENTAL
Intervention: Sorafenib in patients with prior cytokine therapy
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Sorafenib in cytokine-naïve patients
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo in patients with prior cytokine therapy
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo in cytokine-naïve patients
Number of subjects: 903
Study: 18755514

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-60 mg daily, flexible-dose)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 518
Study: 16780494

Group type: EXPERIMENTAL
Intervention: 1072-nm light treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14645972

Group type: EXPERIMENTAL
Intervention: Endobronchial biopsy during bronchoscopy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Bronchoscopy without endobronchial biopsy (Control)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Endobronchial biopsy
Number of subjects: 33
Study: 10808173

Group type: EXPERIMENTAL
Intervention: Allergen nasal challenges
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo nasal challenges
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Allergen and Placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Allergen group
Number of subjects: 20
Study: 8822535

Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: dextroamphetamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: pemoline
Number of subjects: 45
Study: 1532613

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 4067130

Group type: EXPERIMENTAL
Intervention: 0.5 ppm of sulfur dioxide (SO2) via oral inhalation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5 ppm of sulfur dioxide (SO2) via oronasal inhalation (face mask)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 micrograms/m3 of sulfuric acid (H2SO4)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Filtered air (sham exposure)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5 ppm of sulfur dioxide (SO2)
Number of subjects: 10
Study: 30240978

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive-behavioral therapy (CBT4CBT) plus treatment as usual (TAU)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Outpatient treatment as usual (TAU)
Number of subjects: 19
Study: 29271269

Group type: EXPERIMENTAL
Intervention: Religious trauma-writing condition
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional trauma-writing condition
Number of subjects: 105
Study: 26320407

Group type: EXPERIMENTAL
Intervention: Postpartum SMS reminders
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Barriers to postpartum OGTT completion
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Facilitators for postpartum OGTT completion
Number of subjects: 276
Study: 24439741

Group type: EXPERIMENTAL
Intervention: Interrupted subcuticular suture
Number of subjects: 293

Group type: COMPARATOR
Intervention: Interrupted transdermal suture
Number of subjects: 293
Study: 22960288

Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg, single subcutaneous injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20456282

Group type: EXPERIMENTAL
Intervention: Isometric handgrip contraction at 40% of maximal voluntary contraction force
Number of subjects: 0

Group type: COMPARATOR
Intervention: Additional pressure changes induced by inflating bilateral thigh cuffs
Number of subjects: 0
Study: 18799552

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (23-valent pneumococcal polysaccharide vaccine)
Number of subjects: 340
Study: 15707442

Group type: EXPERIMENTAL
Intervention: Cognitive coping intervention administered over three consecutive days in 20-30 minute sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 12125806

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) and hormone replacement therapy (HRT)
Number of subjects: 0
Study: 10091752

Group type: EXPERIMENTAL
Intervention: Surgery (transthoracic esophagectomy with limited lymphadenectomy)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Radiotherapy (50 gray in 28 fractions followed by a 15-gray boost to the primary tumor)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 99

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 99
Study: 8585885

Group type: EXPERIMENTAL
Intervention: Norplant implants
Number of subjects: 16282
Study: 2140370

Group type: EXPERIMENTAL
Intervention: TCMP‐80 (0.01 mg/kg to 10 mg/kg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: TCMP‐80
Number of subjects: 4
Study: 375686

Group type: EXPERIMENTAL
Intervention: 60 mg mianserin
Number of subjects: 54

Group type: COMPARATOR
Intervention: 150 mg imipramine
Number of subjects: 54
Study: 30945492

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (puncturing specific acupoints below the spinous processes from T3 to T12, once every other day for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group (omeprazole capsules 20 mg, twice a day for 8 weeks)
Number of subjects: 60
Study: 28796688

Group type: EXPERIMENTAL
Intervention: Hysteroscopy first (group A)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Biopsy first (group B)
Number of subjects: 68
Study: 26028518

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT; goserelin 10·8 mg every 3 months for 3 years) plus four cycles of docetaxel (70 mg/m² on day 2) and estramustine (10 mg/kg per day on days 1-5, every 3 weeks)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) only
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Radiotherapy (data available for patients treated with radiotherapy)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Treatment-related deaths
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Second cancers
Number of subjects: 413
Study: 23645180

Group type: EXPERIMENTAL
Intervention: Full-bed DALK
Number of subjects: 64

Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 64
Study: 17265078

Group type: EXPERIMENTAL
Intervention: Tiagabine (15 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tiagabine alone
Number of subjects: 20
Study: 14692927

Group type: COMPARATOR
Intervention: Post punch‐grafting PUVA (group I)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Post punch‐grafting topical application of fluocinolone acetonide 0.1% (group II)
Number of subjects: 42
Study: 11009194

Group type: EXPERIMENTAL
Intervention: Cued physical therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-cued physical therapy
Number of subjects: 20
Study: 9180192

Group type: EXPERIMENTAL
Intervention: 40 microg and 20 microg doses at 0 and 6 months
Number of subjects: 199

Group type: COMPARATOR
Intervention: Three 10-microg doses at 0, 1, and 6 months
Number of subjects: 199
Study: 8238144

Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Aspirin with fourfold thromboxane B2 reduction
Number of subjects: 59

Group type: COMPARATOR
Intervention: Remaining patients without fourfold thromboxane B2 reduction
Number of subjects: 59
Study: 4089575

Group type: EXPERIMENTAL
Intervention: Liquid-formula diet (LFD) for 2 weeks followed by protein-sparing modified fast (PSMF) for 4 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Protein-sparing modified fast (PSMF) for 6 weeks
Number of subjects: 41
Study: 30063840

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention for asthma management
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard management)
Number of subjects: 100
Study: 30135834

Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: bCBT
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: bMED
Number of subjects: 270

Group type: COMPARATOR
Intervention: WLC
Number of subjects: 270
Study: 27798902

Group type: EXPERIMENTAL
Intervention: Trastuzumab (8 mg/kg) and Paclitaxel (90 mg/m2) every three weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Genomic analysis
Number of subjects: 3
Study: 25427305

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cyanoacrylate glue
Number of subjects: 30
Study: 22104603

Group type: EXPERIMENTAL
Intervention: Breathmobile plus FACI
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: FACI only
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Breathmobile only
Number of subjects: 322

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 322
Study: 20225477

Group type: EXPERIMENTAL
Intervention: Gel-to-foam dentifrice (Aquafresh Iso-active)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aquafresh Fresh & Minty (Control)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aquafresh Extreme Clean (Control)
Number of subjects: 36
Study: 17381486

Group type: EXPERIMENTAL
Intervention: EMLA cream (2.5 g)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 15367249

Group type: EXPERIMENTAL
Intervention: 150 mg of bupropion SR daily and PTC (n=382)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: 300 mg of bupropion SR daily and PTC (n=383)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: 150 mg of bupropion SR daily and TM (n=381)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: 300 mg of bupropion SR daily and TM (n=378)
Number of subjects: 1524
Study: 11318882

Group type: EXPERIMENTAL
Intervention: Tizanidine hydrochloride tablets (median daily dose of 14 mg, mean 13.5 mg, SD 4.3, range 4 to 20 mg, divided over three doses per day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tizanidine hydrochloride tablets
Number of subjects: 39
Study: 9840539

Group type: EXPERIMENTAL
Intervention: High fiber supplement
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Trained volunteers (VARs)
Number of subjects: 119
Study: 8126535

Group type: EXPERIMENTAL
Intervention: Automated breath-by-breath method
Number of subjects: 10

Group type: COMPARATOR
Intervention: Graphic manual recording
Number of subjects: 10
Study: 2777852

Group type: EXPERIMENTAL
Intervention: Ender nailing
Number of subjects: 60

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 60
Study: 1152797

Group type: EXPERIMENTAL
Intervention: VIDaP-scheme
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: cytosinarabinosid
Number of subjects: 67

Group type: COMPARATOR
Intervention: methotrexat-purinethol-prednisone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: patients below 20 years old
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: patients over 60 years old
Number of subjects: 67
Study: 31133494

Group type: EXPERIMENTAL
Intervention: Three consecutive monthly treatments with selamectin (5.25–6.60 mg/kg) and sarolaner (0.88–1.10 mg/kg) on Days 0, 30, and 60
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single treatment with fluralaner (34.71–43.08 mg/kg) on Day 0 and placebo on Days 30 and 60
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (vehicle control for Revolution® Plus) on Days 0, 30, and 60
Number of subjects: 24